DGAP-News: MOLOGEN AG: Good tolerance of the colorectal cancer medication MGN1703 in phase II/III study - data will be presented at the symposium of ASCO in San Francisco.
(firmenpresse) - DGAP-News: MOLOGEN AG / Key word(s): Miscellaneous
MOLOGEN AG: Good tolerance of the colorectal cancer medication MGN1703
in phase II/III study - data will be presented at the symposium of
ASCO in San Francisco.
21.01.2011 / 10:00
---------------------------------------------------------------------
Leading oncologists from throughout the world will come together on these
days for the Gastrointestinal Cancers Symposium in San Francisco, in order
to share information about the latest scientific breakthroughs. Particular
attention should also be given to the development of the colorectal cancer
medication MGN1703 from MOLOGEN AG, which is currently in a phase II/III
clinical study.
Berlin, 01/21/2011 - MOLOGEN AG will be reporting at the 2011
Gastrointestinal Cancers Symposium in San Francisco on their clinical study
of the intestinal cancer medication MGN1703. This symposium of the American
Society of Clinical Oncology (ASCO) is the central panel for
gastro-intestinal cancer illnesses, where oncologists from the entire world
will come to be informed about the research results of their colleagues.
According to the statements of the researchers from MOLOGEN AG, the
clinical study for MGN1703, for which the interim evaluation is expected in
mid-year, has shown very good tolerance up until now. This is worth noting,
because for this current study phase the highest dosage from the previous
phase 1b was selected and continued. The applied dosage is approx. 5-10x
higher than the dosage which has been used up to now by competitors in
clinical studies. The dSLIM(R) DNAmolecule that was developed and patented
by MOLOGEN is extremely low on side effects thanks to its unique structure,
making this dosage possible.
Dr. Matthias Schroff, scientist and chairman of the board of MOLOGEN AG
comments: 'We are pleased that our colorectal cancer medication is being
well tolerated during the current study. This encourages us in our efforts
to offer future patients a cancer medication without significant side
effects.'
The cancer medication MGN1703 is currently being investigated in the course
of a phase II/III clinical study that is relevant for the approval in the
treatment of metastasized colorectal cancer. The goal of the study is to
significantly prevent the progression of the cancer significantly longer
than has been possible with the treatment methods up to now. The study is
currently being conducted at various study centers in Germany, France and
Austria. The first results will tentatively be available after an interim
evaluation in mid 2011.
Patient information
www.mologen.com/data/Deutsch/09_01_Patienteninfo
Product information and study centers
www.mologen.com/data/Deutsch/09_02_MGN1703
Study portal
The study is recorded on all relevant Internet portals. To overview see
website:
www.mologen.unternehmenskommunikation.com/D/studienportale
Hotline
A study hotline at MOLOGEN AG for MGN1703 provides information individually
and in strict confidence in accordance with medical discretion to
interested doctors and patients on: +49 (0)800 646 1703
www.mologen.com
About MOLOGEN AG
MOLOGEN AG, a German bio-pharmaceutical company based in Berlin,
specializes in the research and development of innovative medicaments based
on DNA structures. Activities focus on numerous product developments
relevant to the immune system, on the one hand vaccines against serious
infections and on the other hand cancer medicaments. MOLOGEN AG is one of
the few biotechnology companies worldwide with a well-compatible DNA-based
cancer treatment in the clinical development stage.
Stock in MOLOGEN AG is listed in the Prime Standard of the German stock
exchange
(ISIN DE 0006637200).
Association memberships:
BIO Deutschland e.V. | DECHEMA - Gesellschaft für Chemische Technik und
Biotechnologie e.V. | Deutsche Industrievereinigung Biotechnologie (DIB)
| Stifterverband für die Deutsche Wissenschaft e.V. | Vereinigung
deutscher Biotechnologie-Unternehmen (VBU) | Verband Forschender
Arzneimittelhersteller e.V. (VFA) | Verband der Chemischen Industrie e.V.
(VCI)
MIDGE(R), dSLIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG.
MOLOGEN AG
PRESS SERVICE
Prof. Peter W. Hübner
Head of Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
huebner(at)mologen.com
INVESTOR RELATIONS:
Jörg PetraßTel: +49 - 30 - 84 17 88 - 13
Fax: +49 - 30 - 84 17 88 - 50
investor(at)mologen.com
External Investor Relations
Kirchhoff Consult AG
Janina Wismar M.A.
Tel: +49 - 40 - 60 91 86 - 50
Fax: +49 - 40 - 60 91 86 - 16
janina.wismar(at)kirchhoff.de
Risk notice regarding forward-looking statements
Certain statements in this report contain forward-looking expressions or
corresponding expressions with negation or deviating versions thereof or
comparable terminology, these are designated as forward-looking statements.
In addition, all information given here that relates to planned or future
results from business sectors, financial figures, developments of the
financial situation or other financial figures or statistical statements,
contain such forward-looking statements. The company advises potential
investors to not rely on these forward-looking statements as a prediction
of actual future events. The company is not obliged to update these
forward-looking statements that only reflect the situation on the day of
publication, and rejects any liability therefor.
End of Corporate News
---------------------------------------------------------------------
21.01.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Deutschland
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: info(at)mologen.com
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
109621 21.01.2011
Datum: 21.01.2011 - 10:00 Uhr
Sprache: Deutsch
News-ID 33038
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 275 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: MOLOGEN AG: Good tolerance of the colorectal cancer medication MGN1703 in phase II/III study - data will be presented at the symposium of ASCO in San Francisco."
steht unter der journalistisch-redaktionellen Verantwortung von
MOLOGEN AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
